Raymond James analyst Steven Seedhouse upgraded CymaBay Therapeutic (NASDAQ: CBAY) from Outperform to Strong Buy with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Upgrades Momentum Movers Trader Talk Upgrades

Cantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold LiftedJuly 23, 2020 10:35 AM CymaBay Therapeutics (CBAY) Announces FDA Lifts All Clinical Holds on SeladelparJuly 23, 2020 8:04 AM FDA Lifts All Clinical Holds on SeladelparJuly 23, 2020 8:00 AM